Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
Condition(s):Corneal NeovascularizationLast Updated:September 16, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Corneal NeovascularizationLast Updated:September 16, 2019Terminated
Condition(s):Pressure Ulcer; Bedsore; Spinal Cord Injury; ParaplegiaLast Updated:April 6, 2020Terminated
Condition(s):Corneal NeovascularizationLast Updated:December 2, 2011Completed
Condition(s):Corneal Neovascularization; Corneal Graft Failure; Anterior Segment InflammationLast Updated:August 5, 2016Withdrawn
Condition(s):Corneal NeovascularisationLast Updated:December 2, 2015Unknown status
Condition(s):Choroidal Neovascularization; Mineralocorticoid ExcessLast Updated:June 19, 2020Not yet recruiting
Condition(s):Corneal NeovascularizationLast Updated:October 15, 2009Unknown status
Condition(s):Corneal NeovascularizationLast Updated:November 8, 2007Completed
Condition(s):Pathological AngiogenesisLast Updated:November 15, 2016Unknown status
Condition(s):Corneal NeovascularizationLast Updated:July 22, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.